Answers are grounded in this paper and cite their sources.
Thyroid eye disease (TED) is a debilitating, vision threatening disease that dramatically alters patients' quality of life. Until recently, the management of TED is a long arduous course with supportive therapy, followed by an extensive surgical treatment plan to reverse the disease endpoints. Teprotumumab offers an early, safe therapeutic intervention to help reverse disease end points such as diplopia and proptosis and improve quality of life.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: